drugset / Trial / NCT02371941

Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis

NCT02371941

Phase 4 Completed 16 enrolled University of Tennessee
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled study of oral cromolyn sodium when made into a viscous preparation for the treatment of eosinophilic esophagitis.

Timeline

Start
2014-12
Primary completion
2017-07
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cromolyn Small molecule 100 mg Oral
Subject Cromolyn Small molecule 200 mg Oral